Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...

Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding ...

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.

Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a ...

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.